Skip to main content
Acticor Biotech logo

Acticor Biotech — Investor Relations & Filings

Ticker · ALACT ISIN · FR0012519668 LEI · 969500K433EK1G89EV95 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2024-10-14 Board/Management Inform…
Country FR France
Listing PA ALACT

About Acticor Biotech

https://www.acticor-biotech.com

Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Board/Management Information Classification · 100% confidence The document is a press release dated October 14, 2024. The primary content announces the appointment of a new Chief Financial Officer (François Guillet). This directly relates to changes in senior management. Although the document also mentions the upcoming Annual General Meeting (AGM) and provides a reminder about receivership proceedings, the main headline and focus of the initial announcement is the executive change. According to the definitions, 'Board/Management Information' (MANG) covers the announcement of changes in senior management. The mention of the AGM documents being available is secondary information, and since the document is an announcement itself, it is not the AGM material (AGM-R) or the proxy statement (PSI). Therefore, MANG is the most appropriate classification.
2024-10-14 English
Inside Information / Other news releases
Investor Presentation Classification · 95% confidence The document is a press release dated October 11, 2024, providing an update on clinical developments for the drug glenzocimab in treating myocardial infarction. It details patient recruitment status for the ongoing Phase 2b LIBERATE study and announces the preparation for a new Phase 2 study (GLORIA). This type of communication, focusing on clinical trial progress, strategic updates, and future development plans, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a formal announcement detailing strategic clinical progress rather than just a brief earnings highlight (ER) or a formal regulatory filing (like 10-K or IR), 'Investor Presentation' (IP) is the most fitting category for this detailed strategic update, although it is presented as a press release. It is not a transcript (CT), a formal annual report (10-K), or a simple dividend notice (DIV). Given the depth of clinical and strategic information provided to investors, IP is the best fit among the specific options.
2024-10-11 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated October 11, 2024, providing an update on clinical developments for the drug glenzocimab, specifically mentioning progress in the Phase 2b LIBERATE study and plans for a new Phase 2 GLORIA study related to myocardial infarction (STEMI). It details patient recruitment numbers, expected timelines (Q4 2026 results, Q1 2025 start for GLORIA), and includes commentary from management. This content structure—a formal announcement detailing operational and clinical progress, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on operational updates and clinical milestones rather than just financial results (ER) or being a miscellaneous regulatory notice (RNS), and given the context of a clinical-stage biotech company, it functions as a key operational update. However, none of the specific codes perfectly match a 'Clinical Trial Update' or 'Press Release'. It is not a full financial report (10-K, IR), a presentation (IP), or a transcript (CT). It is an announcement of company progress. Given the options, 'ER' (Earnings Release) is often used broadly for period-end operational updates, but this is more of a clinical/operational update. Since it is a formal announcement providing key operational news, and it is not a specific regulatory form like 10-K or DEF 14A, the most appropriate general category for a significant, non-financial-specific corporate announcement that isn't a report itself is 'RNS' (Regulatory Filings/General Announcement). If 'ER' is interpreted strictly as financial results, 'RNS' is the best fit for this type of corporate news release.
2024-10-11 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 99% confidence The document is a press release dated October 3, 2024, announcing that the Paris Commercial Court has extended the receivership proceedings for ACTICOR BIOTECH. It provides an update on the company's legal/financial status and ongoing clinical trials. This type of announcement, which details significant legal or regulatory actions affecting the company's operations or status, fits best under the 'Legal Proceedings Report' (LTR) category, as receivership is a form of legal proceeding. It is not a standard financial report (10-K, IR, ER) nor a management change (MANG) or dividend notice (DIV). Since it is a specific announcement about a legal/court action, LTR is the most precise fit over the general 'RNS' fallback.
2024-10-03 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release dated October 3, 2024, announcing the extension ('prorogation') of the company's judicial reorganization procedure ('redressement judiciaire') by the Paris Commercial Court. This type of announcement, which details a significant legal/financial event (restructuring/insolvency proceedings) but is not a formal regulatory filing like a 10-K or a detailed financial report (IR/ER), fits best under the general category for regulatory announcements or significant corporate updates that don't match other specific codes. Since it is an announcement regarding a legal/financial status update that isn't explicitly a capital change (CAP), director dealing (DIRS), or M&A (TAR), it falls under the broad 'Regulatory Filings' (RNS) category, which serves as a general announcement fallback for significant, non-standard corporate news. It is too detailed to be a simple Report Publication Announcement (RPA) and does not match any other specific definition.
2024-10-03 French
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release dated September 12, 2024, detailing several corporate events concerning Acticor Biotech, which is under 'redressement judiciaire' (reorganization/insolvency proceedings). 1. It announces an open call for bids (appel d'offres) for a continuation or sale plan related to the insolvency proceedings, mentioning publication in Les Échos. 2. It provides an update on the judicial reorganization timeline. 3. Crucially, it announces the date and agenda for the upcoming Annual General Meeting (Assemblée Générale Ordinaire annuelle et Extraordinaire) on October 25, 2024, including details on voting and document availability. 4. It announces the resumption of stock trading. Since the document primarily serves as a general corporate update covering multiple significant events, including the announcement of an upcoming AGM and ongoing legal/financial restructuring, it does not fit neatly into a single specific financial report category (like 10-K, ER, or IR). However, the announcement of the AGM date, agenda, and voting procedures strongly aligns with the purpose of materials related to shareholder meetings. While it is not the proxy statement (DEF 14A/PSI) itself, it is a significant announcement concerning the meeting. Given the mix of legal/restructuring news and the AGM announcement, and the fact that it is a general press release format, the most appropriate classification among the options is either RNS (Regulatory Filings - general fallback) or potentially related to the AGM/Proxy materials. Reviewing the definitions: - AGM-R: Presentations/materials *shared during* the AGM. This is an announcement *before* the AGM. - PSI: Proxy Solicitation & Information Statement. This document is an announcement *about* the meeting, not the formal solicitation document itself. - RNS: General regulatory announcements and fallback. Because the document is a comprehensive press release covering multiple material events (restructuring, AGM notice, trading resumption), and does not strictly match the definition of a specific report (like 10-K or IR) or the formal proxy document (PSI), the general Regulatory Filings (RNS) category is the most suitable fallback for a broad, material corporate announcement that doesn't fit elsewhere, although the AGM mention is prominent. Given the length and comprehensive nature, it is not an RPA. I will classify this as RNS as it is a broad regulatory/material announcement.
2024-09-12 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.